Raras
Buscar doenças, sintomas, genes...
Adenoma hipofisário
ORPHA:99408CID-10 · D35.2DOENÇA RARA

Um tumor benigno (que não se espalha para outras partes do corpo) que se origina nas células da parte da frente da glândula hipófise. O tumor pode produzir hormônios ou não. O diagnóstico pode ser feito com base em exames de imagem e/ou exames de sangue para medir os hormônios. Por estar localizado numa região do crânio chamada sela turca (onde a hipófise fica), o crescimento do tumor pode pressionar o quiasma óptico (onde os nervos da visão se cruzam) ou atingir o lobo temporal, o terceiro ventrículo e a parte de trás da base do crânio. Um sintoma físico frequentemente associado é a hemianopsia bitemporal (perda da visão periférica nos dois olhos), que pode progredir para uma perda de visão ainda maior.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um tumor benigno (que não se espalha para outras partes do corpo) que se origina nas células da parte da frente da glândula hipófise. O tumor pode produzir hormônios ou não. O diagnóstico pode ser feito com base em exames de imagem e/ou exames de sangue para medir os hormônios. Por estar localizado numa região do crânio chamada sela turca (onde a hipófise fica), o crescimento do tumor pode pressionar o quiasma óptico (onde os nervos da visão se cruzam) ou atingir o lobo temporal, o terceiro ventrículo e a parte de trás da base do crânio. Um sintoma físico frequentemente associado é a hemianopsia bitemporal (perda da visão periférica nos dois olhos), que pode progredir para uma perda de visão ainda maior.

Pesquisas ativas
30 ensaios
143 total registrados no ClinicalTrials.gov
Publicações científicas
10.625 artigos
Último publicado: 2026 Apr 16
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D35.2
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
42 sintomas
🧠
Neurológico
14 sintomas
🦴
Ossos e articulações
14 sintomas
🧬
Pele e cabelo
12 sintomas
❤️
Coração
11 sintomas
👁️
Olhos
9 sintomas

+ 94 sintomas em outras categorias

Características mais comuns

Aumento do nível circulante de ACTH
Ansiedade
Sinofris
Mãos grandes
Macrotia
Bochechas cheias
231sintomas
Sem dados (231)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 231 características clínicas mais associadas, ordenadas por frequência.

Aumento do nível circulante de ACTHIncreased circulating ACTH level
AnsiedadeAnxiety
SinofrisSynophrys
Mãos grandesLarge hands
Macrotia

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico10.625PubMed
Últimos 10 anos200publicações
Pico2026123 papers
Linha do tempo
2026Hoje · 2026🧪 1979Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

11 genes identificados com associação a esta condição.

USP8Ubiquitin carboxyl-terminal hydrolase 8Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Hydrolase that can remove conjugated ubiquitin from proteins and therefore plays an important regulatory role at the level of protein turnover by preventing degradation. Converts both 'Lys-48' an 'Lys-63'-linked ubiquitin chains. Catalytic activity is enhanced in the M phase. Involved in cell proliferation. Required to enter into S phase in response to serum stimulation. May regulate T-cell anergy mediated by RNF128 via the formation of a complex containing RNF128 and OTUB1. Probably regulates t

LOCALIZAÇÃO

CytoplasmNucleusEndosome membraneCell membrane

VIAS BIOLÓGICAS (4)
Downregulation of ERBB2:ERBB3 signalingRegulation of FZD by ubiquitinationNegative regulation of MET activityUb-specific processing proteases
MECANISMO DE DOENÇA

Pituitary adenoma 4, ACTH-secreting

A form of pituitary adenoma, a neoplasm of the pituitary gland and one of the most common neuroendocrine tumors. Pituitary adenomas are clinically classified as functional and non-functional tumors, and manifest with a variety of features, including local invasion of surrounding structures and excessive hormone secretion. Functional pituitary adenomas are further classified by the type of hormone they secrete. PITA4 results in excessive production of adrenocorticotropic hormone. This leads to hypersecretion of cortisol by the adrenal glands and ACTH-dependent Cushing syndrome. Clinical manifestations of Cushing syndrome include facial and truncal obesity, abdominal striae, muscular weakness, osteoporosis, arterial hypertension, diabetes.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
10.4 TPM
Linfócitos
9.2 TPM
Nervo tibial
9.1 TPM
Cervix Endocervix
8.7 TPM
Ovário
8.3 TPM
OUTRAS DOENÇAS (2)
Cushing disease due to pituitary adenomaautosomal recessive spastic paraplegia type 59
HGNC:12631UniProt:P40818
BRAFSerine/threonine-protein kinase B-rafCandidate gene tested inAltamente restrito
FUNÇÃO

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)

LOCALIZAÇÃO

NucleusCytoplasmCell membrane

VIAS BIOLÓGICAS (4)
Spry regulation of FGF signalingParadoxical activation of RAF signaling by kinase inactive BRAFARMS-mediated activationSignalling to p38 via RIT and RIN
OUTRAS DOENÇAS (18)
Noonan syndrome 7LEOPARD syndrome 3melanoma, cutaneous malignant, susceptibility to, 1lung cancer
HGNC:1097UniProt:P15056
USP48Ubiquitin carboxyl-terminal hydrolase 48Candidate gene tested inAltamente restrito
FUNÇÃO

Deubiquitinase that recognizes and hydrolyzes the peptide bond at the C-terminal Gly of ubiquitin. Involved in the processing of polyubiquitin precursors as well as that of ubiquitinated proteins (PubMed:16214042, PubMed:34059922). Plays a role in the regulation of NF-kappa-B activation by TNF receptor superfamily via its interactions with RELA and TRAF2. May also play a regulatory role at postsynaptic sites. Plays an important role in cell cycle progression by deubiquitinating Aurora B/AURKB an

LOCALIZAÇÃO

CytoplasmNucleusCell projection, cilium

VIAS BIOLÓGICAS (1)
Ub-specific processing proteases
MECANISMO DE DOENÇA

Deafness, autosomal dominant, 85

A form of non-syndromic, sensorineural hearing loss. Sensorineural hearing loss results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA85 is characterized by progressive hearing loss, with onset in childhood or young adulthood.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
68.8 TPM
Cérebro - Hemisfério cerebelar
55.8 TPM
Cerebelo
55.3 TPM
Ovário
36.8 TPM
Glândula adrenal
35.5 TPM
OUTRAS DOENÇAS (3)
hearing loss, autosomal dominant 85autosomal dominant nonsyndromic hearing lossCushing disease due to pituitary adenoma
HGNC:18533UniProt:Q86UV5
TP53Cellular tumor antigen p53Candidate gene tested inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop

LOCALIZAÇÃO

CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (10)
TP53 Regulates Metabolic GenesRegulation of TP53 ExpressionRegulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.0 TPM
Skin Sun Exposed Lower leg
37.0 TPM
Skin Not Sun Exposed Suprapubic
35.2 TPM
Fibroblastos
32.9 TPM
Ovário
32.4 TPM
OUTRAS DOENÇAS (29)
Li-Fraumeni syndromenasopharyngeal carcinoma, susceptibility to, 1hepatocellular carcinomafamilial pancreatic carcinoma
HGNC:11998UniProt:P04637
MEN1MeninCandidate gene tested inAltamente restrito
FUNÇÃO

Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptionDeactivation of the beta-catenin transactivating complexFormation of the beta-catenin:TCF transactivating complexFormation of WDR5-containing histone-modifying complexes
MECANISMO DE DOENÇA

Familial multiple endocrine neoplasia type I

Autosomal dominant disorder characterized by tumors of the parathyroid glands, gastro-intestinal endocrine tissue, the anterior pituitary and other tissues. Cutaneous lesions and nervous-tissue tumors can exist. Prognosis in MEN1 patients is related to hormonal hypersecretion by tumors, such as hypergastrinemia causing severe peptic ulcer disease (Zollinger-Ellison syndrome, ZES), primary hyperparathyroidism, and acute forms of hyperinsulinemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
45.1 TPM
Tireoide
43.2 TPM
Cérebro - Hemisfério cerebelar
40.2 TPM
Fibroblastos
37.9 TPM
Baço
35.0 TPM
OUTRAS DOENÇAS (7)
multiple endocrine neoplasia type 1pituitary gigantismnull pituitary adenomaprolactin-producing pituitary gland adenoma
HGNC:7010UniProt:O00255
AIPSmall ribosomal subunit protein bS22, mitochondrialDisease-causing germline mutation(s) inModerado
FUNÇÃO

May act as a negative regulator of Aurora-A kinase, by down-regulation through proteasome-dependent degradation

LOCALIZAÇÃO

Mitochondrion matrixNucleus

VIAS BIOLÓGICAS (2)
Aryl hydrocarbon receptor signallingGene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
OUTRAS DOENÇAS (7)
growth hormone secreting pituitary adenoma 1familial isolated pituitary adenomapituitary gigantismsilent pituitary adenoma
HGNC:358UniProt:Q9NWT8
GNASProtein ALEXDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

May inhibit the adenylyl cyclase-stimulating activity of guanine nucleotide-binding protein G(s) subunit alpha which is produced from the same locus in a different open reading frame

LOCALIZAÇÃO

Cell membraneCell projection, ruffle

VIAS BIOLÓGICAS (10)
G alpha (s) signalling eventsProstacyclin signalling through prostacyclin receptorADORA2B mediated anti-inflammatory cytokines productionGPER1 signalingG alpha (i) signalling events
EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
1324.4 TPM
Tireoide
727.3 TPM
Hipotálamo
548.6 TPM
Brain Frontal Cortex BA9
501.2 TPM
Cérebro - Hemisfério cerebelar
474.1 TPM
OUTRAS DOENÇAS (12)
progressive osseous heteroplasiapituitary adenoma 3, multiple typespseudohypoparathyroidism type 1CMcCune-Albright syndrome
HGNC:4392UniProt:P84996
NR3C1Glucocorticoid receptorCandidate gene tested inAltamente restrito
FUNÇÃO

Receptor for glucocorticoids (GC) (PubMed:27120390, PubMed:37478846). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors (PubMed:28139699). Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling (PubMed:9590696). Plays a role in rapid mRNA degradation by binding to the 5' UTR of ta

LOCALIZAÇÃO

CytoplasmNucleusMitochondrionCytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, microtubule organizing center, centrosomeChromosomeNucleus, nucleoplasm

VIAS BIOLÓGICAS (6)
PTK6 ExpressionRegulation of RUNX2 expression and activityRegulation of NPAS4 gene transcriptionFOXO-mediated transcription of oxidative stress, metabolic and neuronal genesSUMOylation of intracellular receptors
MECANISMO DE DOENÇA

Glucocorticoid resistance, generalized

An autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of Cushing syndrome typical signs. Clinical features include hypoglycemia, hypertension, metabolic alkalosis, chronic fatigue and profound anxiety.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
55.3 TPM
Nervo tibial
34.5 TPM
Tecido adiposo
34.1 TPM
Fibroblastos
33.6 TPM
Artéria tibial
32.7 TPM
OUTRAS DOENÇAS (2)
glucocorticoid resistanceCushing disease due to pituitary adenoma
HGNC:7978UniProt:P04150
ATRXTranscriptional regulator ATRXCandidate gene tested inAltamente restrito
FUNÇÃO

Involved in transcriptional regulation and chromatin remodeling. Facilitates DNA replication in multiple cellular environments and is required for efficient replication of a subset of genomic loci. Binds to DNA tandem repeat sequences in both telomeres and euchromatin and in vitro binds DNA quadruplex structures. May help stabilizing G-rich regions into regular chromatin structures by remodeling G4 DNA and incorporating H3.3-containing nucleosomes. Catalytic component of the chromatin remodeling

LOCALIZAÇÃO

NucleusChromosome, telomereNucleus, PML body

VIAS BIOLÓGICAS (2)
Inhibition of DNA recombination at telomereDefective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations
MECANISMO DE DOENÇA

Alpha-thalassemia/impaired intellectual development syndrome, X-linked

A disorder characterized by severe psychomotor retardation, facial dysmorphism, urogenital abnormalities, and alpha-thalassemia. An essential phenotypic trait are hemoglobin H erythrocyte inclusions.

OUTRAS DOENÇAS (5)
intellectual disability-hypotonic facies syndrome, X-linked, 1alpha-thalassemia-myelodysplastic syndromealpha thalassemia-X-linked intellectual disability syndromegastric neuroendocrine neoplasm
HGNC:886UniProt:P46100
GPR101Probable G-protein coupled receptor 101Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Orphan receptor

LOCALIZAÇÃO

Cell membrane

MECANISMO DE DOENÇA

Pituitary adenoma 2, growth hormone-secreting

A form of pituitary adenoma, a neoplasm of the pituitary gland and one of the most common neuroendocrine tumors. Pituitary adenomas are clinically classified as functional and non-functional tumors, and manifest with a variety of features, including local invasion of surrounding structures and excessive hormone secretion. Functional pituitary adenomas are further classified by the type of hormone they secrete. PITA2 is a growth hormone-secreting benign neoplasm, also known as somatotropinoma. It clinically results in acromegaly, a condition characterized by coarse facial features, protruding jaw, and enlarged extremities. Excessive production of growth hormone in children or adolescents before the closure of epiphyses causes gigantism, a condition characterized by abnormally tall stature.

EXPRESSÃO TECIDUAL(Baixa expressão)
Brain Nucleus accumbens basal ganglia
4.1 TPM
Hipotálamo
0.8 TPM
Brain Caudate basal ganglia
0.8 TPM
Brain Putamen basal ganglia
0.3 TPM
Cérebro - Hemisfério cerebelar
0.2 TPM
OUTRAS DOENÇAS (2)
pituitary adenoma, growth hormone-secreting, 2acromegaly
HGNC:14963UniProt:Q96P66
CDH23Cadherin-23Candidate gene tested inTolerante
FUNÇÃO

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells. CDH23 is required for establishing and/or maintaining the proper organization of the stereocilia bundle of hair cells in the cochlea and the vestibule during late embryonic/early postnatal development. It is part of the functional network formed by USH1C, USH1G, CDH23 and MYO7A that mediates mechanotransduction in cochlear hair cells. Required for norma

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Sensory processing of sound by outer hair cells of the cochleaSensory processing of sound by inner hair cells of the cochlea
MECANISMO DE DOENÇA

Usher syndrome 1D

USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness.

OUTRAS DOENÇAS (12)
autosomal recessive nonsyndromic hearing loss 12Usher syndrome type 1Dnonsyndromic genetic hearing lossUsher syndrome
HGNC:13733UniProt:Q9H251

Variantes genéticas (ClinVar)

4,104 variantes patogênicas registradas no ClinVar.

🧬 CDH23: NM_022124.6(CDH23):c.5629G>A (p.Asp1877Asn) ()
🧬 CDH23: NM_022124.6(CDH23):c.9949G>A (p.Ala3317Thr) ()
🧬 CDH23: NM_022124.6(CDH23):c.1526del (p.Asp509fs) ()
🧬 CDH23: NM_022124.6(CDH23):c.3396C>T (p.Gly1132=) ()
🧬 CDH23: NM_022124.6(CDH23):c.1624G>T (p.Glu542Ter) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 536 variantes classificadas pelo ClinVar.

295
241
Patogênica (55.0%)
VUS (45.0%)
VARIANTES MAIS SIGNIFICATIVAS
GNAS: NM_000516.7(GNAS):c.585+1G>C [Pathogenic]
GNAS: NM_000516.7(GNAS):c.433-2A>C [Pathogenic/Likely pathogenic]
CDH23: NM_022124.6(CDH23):c.9634-1G>A [Likely pathogenic]
CDH23: NM_022124.6(CDH23):c.9511-2A>C [Likely pathogenic]
CDH23: NM_022124.6(CDH23):c.9207dup (p.Ile3070fs) [Likely pathogenic]

Vias biológicas (Reactome)

79 vias biológicas associadas aos genes desta condição.

Downregulation of ERBB2:ERBB3 signaling Regulation of FZD by ubiquitination Ub-specific processing proteases Negative regulation of MET activity Spry regulation of FGF signaling Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation Formation of the beta-catenin:TCF transactivating complex SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Deactivation of the beta-catenin transactivating complex Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) RHO GTPases activate IQGAPs Post-translational protein phosphorylation Formation of WDR5-containing histone-modifying complexes Mitochondrial translation initiation Mitochondrial translation elongation Mitochondrial translation termination Mitochondrial ribosome-associated quality control GNAS1 GNAS2 GNAS G alpha (s):GTP:SRC dissociates G alpha (s):GTP:SRC catalyzes SRC to p-Y419-SRC G protein alpha (s):GTP binds SRC HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Nuclear Receptor transcription pathway SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado4
1Fase 11
·Pré-clínico15
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Adenoma hipofisário

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

19 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT04569591 · DDAVP for Pituitary AdenomaRecrutando
NA
NCT06353529 · Postop Pain Management in Pituitary Tumour PatientsRecrutando
PHASE4
NCT07456878 · Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying …Recrutando
PHASE1
NCT04278118 · Hypofractionated Proton Therapy for Benign Intracranial Brai…Recrutando
NA
NCT07335315 · Evaluation of Intraoperative Contrast Enhanced Ultrasound fo…Recrutando
NCT06584123 · Molecular Pituitary Imaging Using 18F-FET PETRecrutando
NA
NCT04081701 · 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of So…Recrutando
PHASE4
NCT07179926 · Effects of Pasireotide Lar Therapy on Bone MetabolismRecrutando
NCT06163261 · Individualized Physical Activity or Patients With Non Functi…Recrutando
NA
NCT06831461 · Proton Versus Photon Radiotherapy in Adults With Primary Bra…Recrutando
NA
NCT06973824 · A Twenty-years' Experience in Pituitary Disease.Recrutando
NCT00461188 · Genetics of Endocrine Tumours - Familial Isolated Pituitary …Recrutando
NCT06949891 · KETOgenic Diet Therapy in Patients With ACROmegalyRecrutando
NA
NCT06874426 · The Impact of Endoscopic Endonasal Skull Base Surgery on Olf…Recrutando
NCT06679816 · Hydrocortisone in Hormone Replacement Therapy for Large Pitu…Recrutando
PHASE4
NCT05254197 · SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)Recrutando
NCT06523582 · Genetic Bases of Neuroendocrine Neoplasms in Mexican Patient…Recrutando
NCT06297473 · Physical Attendance Versus Telephone or Video Follow-up in P…Por convite
NA
NCT07034859 · Cabergoline in the Management of Nonfunctioning Pituitary Ad…Por convite
PHASE4

Outros ensaios clínicos

143 ensaios clínicos encontrados, 30 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
5.345 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 5.345

#1

Long-term trajectories of cognitive function, fatigue, and quality of life in patients after pituitary adenoma surgery: A retrospective study.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia2026 Mar 20

Pituitary adenomas (PAs) are common intracranial tumors where surgery is the primary treatment. While effective, many patients face persistent cognitive deficits, chronic fatigue, and diminished health-related quality of life (HRQoL) long after resection. Current literature lacks dynamic, long-term perspectives on how these heterogeneous outcomes evolve and interact over time. This single-center retrospective cohort study (N = 295) tracked patients between June 2021 and December 2024 who underwent first-time PA resection. Longitudinal assessments from 6 months to 5 years postoperatively included the Montreal Cognitive Assessment (MoCA), Fatigue Severity Scale (FSS), and SF-36 survey. Latent class growth analysis (LCGA) was employed to identify distinct recovery trajectories. Multinomial logistic regression identified baseline predictors, and chi-square tests analyzed inter-trajectory associations. LCGA identified heterogeneous patterns: three classes for cognition (Stable-High, 54.9%; Moderate-Improving, 33.2%; Persistent-Deficient, 11.9%), three for fatigue, and distinct pathways for HRQoL. Key predictors for poor recovery trajectories included older age, lower education, Cushing's disease, and the need for postoperative hormone replacement. Notably, severe chronic fatigue was a potent predictor of poor mental HRQoL (aOR = 8.15, 95% CI: 3.50-18.99). A robust "symptom cluster" was identified, where cognitive impairment and severe fatigue consistently co-occurred with poor life satisfaction. Recovery after pituitary surgery follows diverse, interrelated long-term trajectories rather than a uniform path. Identifying this specific postoperative symptom cluster underscores the necessity of integrated, holistic management. Our findings facilitate early risk stratification and provide a foundation for developing personalized rehabilitation strategies targeting vulnerable patient populations.

#2

AI at the Sella Turcica: Multi-Model Large Language Model Evaluation in Pituitary Adenomas.

Brain & spine2026

Large language models (LLMs) are explored as clinical decision-support tools in complex medical fields. However, their reliability and clinical usefulness in multidisciplinary management of pituitary adenomas remain insufficiently evaluated using validated, clinician-based frameworks. Do LLMs differ in informational quality, clinical reasoning, and expert satisfaction when applied to pituitary adenoma-related clinical scenarios? A prospective comparative study evaluated three LLMs: ChatGPT-5.0, Claude Opus 4.1, and Gemini 2.5 Flash. A standardized prompt set covering general knowledge, surgical decision-making, endocrine evaluation, patient education, and MRI-based scenarios was submitted to each model identically. Outputs were anonymized and independently assessed by 10 board-certified doctors using three validated instruments: the Quality Assessment of Medical Artificial Intelligence (QAMAI), the Artificial Intelligence Performance Instrument (AIPI), and the Artificial Intelligence Satisfaction and Performance Evaluation Questionnaire (AISPE-Q). Claude Opus 4.1 achieved the highest performance across all major domains. Aggregate QAMAI scores were highest for Claude Opus 4.1 (4.39 ± 0.66), compared with ChatGPT-5.0 (4.12 ± 0.74) and Gemini 2.5 Flash (4.07 ± 0.76; p = 0.018). Clinical reasoning assessed by AIPI was superior for Claude Opus 4.1 versus Gemini 2.5 Flash and ChatGPT-5.0. Strong correlations were observed between informational quality, reasoning performance, and satisfaction. LLMs exhibit significant variability in performance when managing pituitary adenomas. Claude Opus 4.1 demonstrated the highest levels of informational quality, reasoning depth, and expert trust. While LLMs may serve as supportive adjuncts in multidisciplinary pituitary care, structured evaluation and expert oversight remain essential before clinical integration. 2 - Prospective comparative diagnostic accuracy study.

#3

Case Report: Treatment of hypersomatotropism in a diabetic dog with transsphenoidal hypophysectomy.

Frontiers in veterinary science2026

Pituitary somatotroph adenoma is rare in dogs and may cause hypersomatotropism (HS) leading to insulin resistance and diabetes mellitus (DM). A 10-year-5-month-old neutered male Staffordshire Bull Terrier presented with polyuria, polydipsia, progressive inspiratory stridor, and poorly controlled DM with hyperinsulinemia and insulin resistance. Serum insulin-like growth factor (IGF-1) was markedly elevated (1,214 ng/mL; reference interval, 42-449 ng/mL) and suggested HS which was further supported by a somatostatin suppression test. Magnetic resonance and computed tomography (CT) imaging revealed a pituitary mass, organomegaly, and arthropathy. The pituitary mass was removed by transsphenoidal hypophysectomy. Immunohistochemistry confirmed a growth hormone (GH)-producing pituitary adenoma. Postoperatively, GH normalized within hours, and IGF-1 values within a week. Although HS resolved and hyperinsulinemia improved postoperatively, the dog remained dependent on insulin and DM persisted which eventually led to euthanasia of the dog about 9 and a half months post-operatively. Transsphenoidal hypophysectomy was effective in normalization of GH and IGF-1 concentrations in a dog diagnosed with a pituitary somatotroph adenoma but the postoperative course was characterized by persistent insulin dependency and DM.

#4

Regression of pituitary macroadenoma after endovascular embolization of thoracic cerebrospinal fluid-venous fistula for symptomatic intracranial hypotension: Illustrative case.

Surgical neurology international2026

Pituitary hyperemia and gland enlargement can be cardinal features of intracranial hypotension secondary to cavernous sinus and epidural venous plexus distention. This phenomenon can therefore complicate radiographic interpretation of sellar lesions when both diagnoses co-exist. We report a unique case of a rapidly enlarging pituitary macroadenoma in the setting of a thoracic cerebrospinal fluid (CSF)-venous fistula causing symptomatic intracranial hypotension. A 53-year-old female with no prior neurosurgical history presented with recurrent orthostatic headache. Magnetic resolution imaging revealed a pituitary lesion along with pathopneumonic signs of intracranial hypotension. The tumor grew rapidly on surveillance imaging, prompting consideration of surgery. Further work-up, however, revealed a thoracic CSF-venous fistula. Endovascular embolization of the fistula led to near-complete resolution of her symptoms and durable radiographic tumor regression. Pituitary macroadenomas are susceptible to local hemodynamic changes occurring as a sequelae of occult CSF leak. Identification and treatment of the underlying etiology were sufficient to induce tumor regression.

#5

Intraoperative Visual Evoked Potential Monitoring in Endoscopic Endonasal Surgery for Nonpituitary Adenoma Suprasellar Tumors.

Journal of clinical neurology (Seoul, Korea)2026 Mar

Intraoperative visual evoked potential (VEP) monitoring has been studied mainly in pituitary adenoma, while its role in nonpituitary suprasellar tumors has remained unclear. This study evaluated the predictive usefulness of intraoperative VEP monitoring during endoscopic endonasal surgery (EES) and aimed to identify optimal alarm criteria for visual outcomes. We retrospectively analyzed a cohort of 87 patients who underwent EES with intraoperative VEP monitoring between April 2021 and September 2023. Visual outcomes were evaluated preoperatively and at short-term (≤3 months) and long-term (12 months) follow-ups, with visual deterioration at these time points defined as worsening of either visual acuity or the visual field. Reductions in the VEP amplitude were quantified using both the maximum intraoperative decrease and the final amplitude after recovery. Receiver operating characteristic (ROC) curve analyses were performed to identify the optimal alarm thresholds, and the sensitivity, specificity, positive predictive value, and negative predictive value were calculated for short-term and long-term visual deteriorations. Short-term and long-term visual deteriorations were detected in 12 (9.2%) and 5 (3.8%) of the 130 analyzed eyes, respectively. ROC curve analyses identified ≥40% and ≥30% reductions in the N75-P100 amplitude as optimal alarm criteria for short-term and long-term visual deteriorations, respectively. A 30% reduction without intraoperative recovery demonstrated markedly higher sensitivity than the conventional 50% alarm threshold for short-term (58.3% vs. 33.3%) and long-term (80.0% vs. 20.0%) outcomes, while maintaining acceptable specificity (82.2% and 80.8%, respectively). A 30% reduction in amplitude represents a more-sensitive and clinically relevant alarm threshold than a 50% reduction for intraoperative VEP monitoring during EES for nonpituitary suprasellar tumors. Incorporating both the magnitude and recovery pattern of VEP amplitude changes may improve the accuracy of predictions of long-term visual deterioration. However, the potential for false positives warrants cautious interpretation, and further studies are needed to validate the impact of intraoperative VEP monitoring on visual outcomes.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC3.759 artigos no totalmostrando 197

2026

Integrated proteomic and metabolomic profiling reveals molecular signatures underlying invasiveness in non-functioning pituitary adenomas.

Oncology letters
2026

Long-term trajectories of cognitive function, fatigue, and quality of life in patients after pituitary adenoma surgery: A retrospective study.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2026

Lumbar spinal stenosis in patients with acromegaly: an MRI-based case-control study.

World neurosurgery
2026

AI at the Sella Turcica: Multi-Model Large Language Model Evaluation in Pituitary Adenomas.

Brain & spine
2026

Nivolumab rechallenge after pituitary apoplexy associated with nivolumab plus ipilimumab in a patient with pituitary adenoma and rectal melanoma: a case report and literature review.

Journal of pharmaceutical health care and sciences
2026

Biochemical and metabolic tissue discrimination using a dual-modality Raman-fluorescence endonasal spectroscopy probe for pituitary adenoma surgery.

Pituitary
2026

Gyrus Rectus Herniation Following Transsphenoidal Pituitary Adenoma Surgery: A Rare Case Report.

Journal of neurological surgery reports
2026

Early Experience With Endoscopic Endonasal Transsphenoidal Surgery for Pituitary Adenomas: Clinical Outcomes and Complications.

The Journal of craniofacial surgery
2026

[Matrix metalloproteinases in pituitary adenoma invasiveness].

Problemy endokrinologii
2026

[Multiple endocrine neoplasia syndrome type 1: analysis of data from 102 patients from 43 families in the population of the Russian Federation].

Problemy endokrinologii
2026

Pathogenesis of Non-Familial Somatotroph Adenomas.

The Journal of clinical endocrinology and metabolism
2026

Hormonal rhythm disturbance is a potential contributor to postoperative cognitive dysfunction of pituitary tumor surgery.

Neuroendocrinology
2026

Coexistence of Intracranial Aneurysm and Pituitary Adenoma: A Case Report and Literature Review.

Cureus
2026

Case Report: Treatment of hypersomatotropism in a diabetic dog with transsphenoidal hypophysectomy.

Frontiers in veterinary science
2026

Sellar Dermoid Cyst Coexistence with Pituitary Adenoma/Pituitary Neuroendocrine Tumor.

Journal of neurological surgery reports
2026

Oxidative phosphorylation patterns in pituitary adenoma/neuroendocrine tumors.

Pituitary
2026

Quality of life questionnaires in patients with acromegaly: a scoping review.

Journal of patient-reported outcomes
2026

Diagnostic Utility of T-PIT, PIT-1, and SF-1 in Differentiating Pituitary Neuroendocrine Tumors From Sinonasal and Skull Base Tumors.

Applied immunohistochemistry & molecular morphology : AIMM
2026

Severe Headache and Acute Blindness: A Case of Pituitary Apoplexy.

Clinical case reports
2026

Crooke Cell Adenoma: Is Its Aggressiveness Overestimated? Evidence From a Single-Centre Experience.

Clinical endocrinology
2026

Proteomic insights into the invasiveness and tumor progression of non-functioning pituitary adenomas: A scoping review.

Journal of neuroendocrinology
2026

Evaluation of static and dynamic pupil responses in patients with acromegaly with automatic pupillometer.

BMC ophthalmology
2026

The clinical value of [18F]-fluoro-ethyl-L-tyrosine PET ([18F]FET-PET) correlated with MRI in patients with functioning pituitary adenomas: an observational cohort study.

Pituitary
2026

Variances in 3D radiomic shape features between meningioma, acoustic neuroma, and pituitary adenoma and the impact on dosimetric plan quality in Gamma Knife stereotactic radiosurgery.

Biomedical physics & engineering express
2026

Regression of pituitary macroadenoma after endovascular embolization of thoracic cerebrospinal fluid-venous fistula for symptomatic intracranial hypotension: Illustrative case.

Surgical neurology international
2025

Conjunction of ovarian dermoid cyst in a patient with Pituitary Micro Adenoma: A Case Report.

JNMA; journal of the Nepal Medical Association
2026

Early postoperative hyponatremia after pituitary adenoma surgery: risk factors, predictive model, and clinical implications.

BMC endocrine disorders
2026

Intraoperative Visual Evoked Potential Monitoring in Endoscopic Endonasal Surgery for Nonpituitary Adenoma Suprasellar Tumors.

Journal of clinical neurology (Seoul, Korea)
2026

Isolated Intracranial Rosai-Dorfman Disease Mimicking Sellar Pituitary Adenoma: a case report and literature review.

BMC neurology
2026

Optical coherence tomography angiography reveals microvascular changes and predicts visual outcomes after decompression surgery for pituitary adenoma.

The British journal of ophthalmology
2026

MALAT1 rs619586 as a potential genetic marker of pituitary adenoma susceptibility and aggressiveness.

Frontiers in endocrinology
2026

Pituitary Apoplexy Following Gonadotropin-Releasing Hormone Agonist Administration for Prostate Cancer.

IJU case reports
2026

Repeat stereotactic radiosurgery for pituitary adenomas: a systematic review and meta-analysis.

Neurosurgical review
2026

DNMT3A R882C variant in a patient with a presumed pineal gland tumor, highlighting potential tumor susceptibility in Tatton-Brown-Rahman syndrome.

Cancer genetics
2026

Effect of preoperative anemia on surgical outcomes in endonasal transsphenoidal surgery for pituitary adenoma: a matched-cohort study.

Acta neurochirurgica
2026

Multiple endocrine neoplasia with an atypical clinical course and a MEN1 gene variant of uncertain pathogenicity: A case report.

Medicine
2026

Xanthomatous hypophysitis with optic chiasm edema: First documented clinical case.

Radiology case reports
2026

Cancer Risk in Patients with Acromegaly: Insights from a Single Center in Ankara.

Journal of clinical medicine
2026

Two-Week Interval Hypofractionated Stereotactic Radiosurgery for Benign Intracranial Tumors: Volumetric Kinetics and Radiobiological Rationale.

Cancers
2026

CDK8 phosphorylates SOX2 to maintain stemness of pituitary adenoma.

Oncogene
2026

Redefining Pituitary Neuroendocrine Tumors in MEN1: Prevalence, Clinical Behavior, and Implications for Long-Term Surveillance.

Current oncology (Toronto, Ont.)
2026

Differences in clinical course between pituitary apoplexy and non-apoplexy patients with nonfunctioning pituitary neuroendocrine tumors.

Neurosurgical review
2026

Bone microarchitecture assessed by HR-pQCT in syndrome of inappropriate secretion of thyrotropin with thyrotoxicosis.

Archives of osteoporosis
2026

A Clival Mass Posing a Diagnostic Challenge: Pituitary Adenoma With Rathke Cleft Cyst Mimicking Chordoma.

Cureus
2026

Mask - Region-based Convolutional Neural Networks (R-CNN) with Radiomics Integration and Gray Level Co-occurrence Matrix (GLCM) for brain tumor detection and segmentation.

PloS one
2026

Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas.

Best practice & research. Clinical endocrinology & metabolism
2026

Oridonin regulates pituitary-derived folliculostellate cells apoptosis via the p38 MAPK/p53 signalling pathway.

European journal of pharmacology
2026

Acromegaly presenting with normal insulin-like growth factor-1 levels in a patient with advanced liver cirrhosis.

BMJ case reports
2026

Acromegaly-induced dilated cardiomyopathy presenting with heart failure as the cardinal symptom: A case report.

SAGE open medical case reports
2026

[68Ga]Ga-DOTATATE PET/CT and PET/MR enhances the detection of pituitary ACTH-secreting adenomas in cushing's disease.

Frontiers in endocrinology
2026

Predicting resection success in giant pituitary adenomas: morphologic determinants and a preoperative multivariate model.

Frontiers in endocrinology
2026

SiCmiR Atlas: Single-Cell miRNA Landscape Reveals Hub-miRNA and Network Signatures in Human Cancers.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2026

Diffusion-based virtual multi-stain staining for pituitary adenoma histopathology.

Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
2026

Multiple endocrine neoplasia type 5: emerging evidence and clinical perspectives.

Endocrine-related cancer
2026

Surgical outcomes of endoscopic endonasal surgery for nonfunctioning pituitary adenoma in elderly patients: a comprehensive analysis beyond age : Surgery for pituitary adenoma among elderly patients.

BMC endocrine disorders
2026

Isolated primary amenorrhea in a 22-year-old female revealing pituitary apoplexy: a rare case report.

Annals of medicine and surgery (2012)
2026

[Lost anatomical structure - pharyngeal pituitary gland (Hypophysis pharyngealis or Erdheim pituitary gland): a review and case report].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2026

A Medically Managed Case of Acromegaly: A Case Report.

Cureus
2026

Histopathological and radiological predictors of surgical remission failure in GH-secreting pituitary adenomas.

Pituitary
2026

Subsequent primary malignancies in patients with initial diagnosis of pituitary adenoma: a surveillance, epidemiology, and end results (SEER) data analysis.

Pituitary
2026

miR-221/222 Facilitate Pituitary Adenoma Progression Via PHACTR4 Downregulation.

Human mutation
2026

Ectopic maxillary ACTH-secreting adenoma complicated by Nelson's syndrome: a case report.

Annales d'endocrinologie
2026

DRD2 Deficiency Underlies Pituitary Adenoma Dependent on Escherichia coli Translocation from the Gut.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2026

Sex-related differences in healthcare utilization and costs among patients with pituitary adenomas.

Pituitary
2026

The Use of Indocyanine Green (ICG) in Endoscopic Pituitary Surgery: A Systematic Review.

Neuro-Chirurgie
2026

Decoy Lesion in Functional Multiple Pituitary Adenomas: Literature Review and Illustrative Cases on Diagnostic Pitfalls and Surgical Strategies.

World neurosurgery
2026

Postoperative days 1 and 2 morning cortisol levels as predictors of long-term secondary adrenal insufficiency following pituitary adenoma surgery.

Journal of neurosurgery
2026

Clinical characteristics associated with somatic GNAS mutations in acromegaly: a systematic review and institutional experience.

Frontiers in endocrinology
2026

Impact of sex on mortality in patients with pituitary adenomas.

Pituitary
2026

Coexistence of Resistance to Thyroid Hormone and a Thyroid Stimulating Hormone-Secreting Pituitary Adenoma.

AACE endocrinology and diabetes
2026

Disease activity and maternal-fetal outcomes in pregnant women with cushing's syndrome: a systematic review and meta‑analysis.

Reviews in endocrine & metabolic disorders
2026

Cavernous Sinus Medial Wall Resection: A Retrospective Single-Institution Study on Outcomes in Functional Pituitary Adenomas.

Operative neurosurgery (Hagerstown, Md.)
2026

The INVasiveness in Pituitary ADEnomas Score: Development and Validation of a Novel Radiographic Grading Scale for Pituitary Adenoma Invasion.

Operative neurosurgery (Hagerstown, Md.)
2026

New Sparks and Spots: Molecular Imaging with Positron Emission Tomography Will Change Management of Cushing's Disease.

Endocrinology and metabolism (Seoul, Korea)
2026

Preoperative Metabolic Predictors of Granulation Subtypes in Somatotroph Tumors: A Multicenter Retrospective Cohort Study.

CNS neuroscience & therapeutics
2026

A Case Report of Growth Hormone-Secreting Pituitary Adenoma Complicated by Apoplexy With Atypical Clinical Presentation.

Case reports in medicine
2025

Lugol's solution for preoperative management of a TSH/GH-secreting pituitary adenoma with suboptimal response to octreotide: a case report.

Frontiers in endocrinology
2026

Mixed gangliocytoma-pituitary neuroendocrine tumour: clinical, immunohistochemical, and molecular genetic profiles in a series of four patients.

Acta neuropathologica communications
2026

Oxidative Phosphorylation in Silent Pituitary Adenomas: A Multiomics Perspective.

International journal of endocrinology
2026

A novel germline CDH23 variant as a likely cause of an ultra-giant prolactinoma.

Orphanet journal of rare diseases
2026

Optimizing glioma vascular analysis: A finetuned masked autoencoder self-attention mechanism approach for accurate and interactive blood vessel segmentation.

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion
2026

Recurrent Pituitary Adenoma Causing Cushing's Disease in a Patient With Lynch Syndrome.

Cureus
2026

Critical views for safe surgical phase progression in endoscopic endonasal transsphenoidal pituitary adenoma resection: modified Delphi consensus.

Pituitary
2026

Learning Curve in Endoscopic Pituitary Surgery: Is Progress over Time Always Guaranteed? A Consecutive Series of 123 Cases from a Single Center.

Journal of clinical medicine
2026

Serum Lipidomic Profile Signature of Active Acromegaly and Relationships to Cardiovascular Disease.

International journal of molecular sciences
2025

Craniofacial and Radiological Features as Diagnostic Clues to Unmask Acromegaly: A Case Report.

Cureus
2026

Comprehensive evaluation and analysis of pituitary hormones in male patients with non-functional pituitary adenoma during the perioperative period.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Machine learning-based models for preoperative prediction of pituitary adenoma consistency: a systematic review and meta-analysis.

Acta neurochirurgica
2026

Diagnosis and surgical management of a pituitary adenoma coexisting with a persistent trigeminal artery: Case report and review of the literature.

Neurocirugia
2026

Radiosurgery in recurrent and persistent Cushing's Disease: a Systematic Review and Meta-Analysis.

Neurosurgical review
2026

The International Classification of Diseases for Oncology, 4th Edition (ICD-O-4): An overview.

Cancer epidemiology
2026

Association of standard postoperative day 1 discharge following endonasal surgery for pituitary adenoma with lower complication rates and unplanned medical care.

Journal of neurosurgery
2025

Thyroid-Stimulating Hormone (TSH)-Secreting Pituitary Macroadenoma Presenting as Biochemical Hyperthyroidism Without Clinical Symptoms: A Case Report.

Cureus
2025

Ectopic Acromegaly Caused by Peripheral Ectopic Growth Hormone Hypersecretion: A Case Report and Literature Review.

Cureus
2025

An overview of hypopituitarism's causes.

Frontiers in endocrinology
2026

Widespread invasion of a giant prolactinoma via valveless venous channels: illustrative case.

Journal of neurosurgery. Case lessons
2026

Collision tumors at the skull base: unveiling a somatotroph pituitary adenoma coexisting with a petroclival meningioma. Illustrative case.

Journal of neurosurgery. Case lessons
2026

Utility of standardized T2-weighted MRI intensity ratio for prediction of pituitary macroadenoma consistency.

Journal of neurosurgery
2026

Gender differences in the glycometabolic and cardiovascular features of acromegaly.

Pituitary
2026

An Investigation of the Effect of Exercise on Sleep Disturbances and Fatigue Symptoms in Patients Diagnosed with Primary Brain Tumors: A Systematic Review.

NeuroSci
2026

Gut microbiota composition and functionality are associated with prolactin-secreting pituitary adenoma and serum lipid levels.

BMC microbiology
2026

Long-term effect on bone mineral density of denosumab in the treatment of hyperpituitarism driven osteoporosis: an exploratory study.

Pituitary
2026

Clinical characteristics and risk factors of delayed ophthalmoplegia following cavernous sinus exploration in endoscopic pituitary adenoma surgery : Delayed transient ophthalmoplegia.

Pituitary
2025

Normal Pituitary Gland Showing an Intratumoral Septal Structure in a Nonfunctioning Pituitary Neuroendocrine Tumor: Illustrative Case.

NMC case report journal
2026

Seeing the unseen: A case series of intracranial mass lesions initially presenting with visual disturbances.

The Journal of international medical research
2026

[Corrigendum] CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas.

International journal of molecular medicine
2025

Sellar and parasellar paraganglioma mimicking pituitary macroadenoma in a young female: A rare case report.

International journal of surgery case reports
2026

Sex and Age Differences in Transcription Factor and Hormonal Immunostaining in Patients With Nonfunctioning Pituitary Adenomas.

Operative neurosurgery (Hagerstown, Md.)
2026

Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas.

Endocrine oncology (Bristol, England)
2025

Pituitary apoplexy in the setting of adrenocorticotropic hormone-secreting adenoma: A systematic review and illustrative case.

Brain circulation
2026

Endoscopic Transsphenoidal Approach for the Treatment of Pituitary Adenoma Complicated With Rathke Cleft Cyst.

The Journal of craniofacial surgery
2026

Histogram analysis based on contrast-enhanced T1-weighted imaging in pituitary macroadenomas: relation to histological subtype and expression.

Quantitative imaging in medicine and surgery
2026

"Doughnut appearance" of macular microcysts due to optic atrophy on optical coherence tomography angiography.

Retinal cases & brief reports
2026

Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis.

Journal of neuro-oncology
2025

Isolated Adrenocorticotropic Hormone Deficiency:Report of Three Cases and Literature Review.

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
2026

Race and Cerebrospinal Fluid Leaks: Concerning Associations after Endonasal Transsphenoidal Pituitary Resection.

Journal of neurological surgery. Part B, Skull base
2026

The Impact of Extended Procedure Duration on Nasal Morbidity after Endoscopic Endonasal Transsphenoidal Resection of Pituitary Macroadenomas.

Journal of neurological surgery. Part B, Skull base
2026

Primary Bilateral Macronodular Adrenal Hyperplasia Associated With ARMC5 Variant and Pituitary Microadenoma.

JCEM case reports
2026

Association between the WHO 2017 and 2022 classification updates and ICD-10 code accuracy in patients with PitNETs: a real-world retrospective study.

BMC endocrine disorders
2026

Acromegaly in an elderly male with hepatic malignancy: a case report of a diagnostic dilemma.

Annals of medicine and surgery (2012)
2026

Surgical and Endocrine Outcomes of Medial Cavernous Sinus Wall Resection in Functioning Pituitary Tumors.

Operative neurosurgery (Hagerstown, Md.)
2026

Case Reports: Exploring the Varied Presentations and Clinical Features of Carney Complex, A Detailed Report on Three Distinct Cases.

Journal of clinical research in pediatric endocrinology
2025

Correlation between intrasellar pressure, pituitary adenoma invasiveness, pituitary dysfunction, and apoplexy.

Frontiers in endocrinology
2025

Phenotypic and functional characteristics of pituitary adenoma stem cells.

World journal of clinical cases
2025

Multiple Endocrine Neoplasia Type 5 due to Germline MAX Mutations: A Systematic Review of Tumor Spectrum and Clinical Features.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

Serum Kynurenine Pathway Metabolites as Candidate Diagnostic Biomarkers for Pituitary Adenoma: A Case-Control Study.

Medicina (Kaunas, Lithuania)
2025

Mixed gangliocytoma-silent somatotroph pituitary adenoma: a rare variant with pregnancy-associated growth.

BMJ case reports
2025

From proliferation to bone invasion: The association between Ki-67 index and histological Sellar floor destruction in pituitary adenomas.

Endocrine
2025

Glucocorticoid-Induced Positive Feedback in Cushing Disease: Insights From a Spanish Multicenter Cohort.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

The surgical management of Cushing disease: a case series from a Canadian tertiary center.

Neurological research
2025

Strong PSMA Expression by a Pituitary Macroadenoma on PSMA PET/CT.

Clinical nuclear medicine
2025

Early Experience of Endoscopic Endonasal Transphenoidal Surgery in the Democratic Republic of Congo: Expanding Access to Skull Base Oncology.

Cureus
2025

Predictive model of delayed hyponatremia after endoscopic endonasal transsphenoidal resection of pituitary adenoma.

Frontiers in human neuroscience
2026

Duration of adrenal insufficiency after surgical treatment of endogenous hypercortisolism: a prospective cohort study.

European journal of endocrinology
2025

Surgical management in very elderly patients with pituitary adenoma: a multivariable assessment of the surveillance, epidemiology, and end results database.

Pituitary
2025

Prospective Observational Study of 118 Clinically Nonfunctioning Pituitary Adenomas.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2026

Functional analysis of AIP variants in a cohort of neuroendocrine neoplasms.

Endocrine-related cancer
2025

Revealing sphingolipid metabolism genes as biomarkers for the diagnosis of invasive pituitary adenomas in silico and in vivo.

European journal of medical research
2025

Anatomical considerations in acromegalic patients: A multicentric cohort study.

Surgical neurology international
2025

Predictors of delayed hyponatremia after endoscopic transsphenoidal surgery for non-functioning pituitary adenomas.

Frontiers in endocrinology
2025

Radiological Differentiation of Pituitary Adenomas From Other Sellar Masses: A Systematic Review.

Cureus
2025

The efficacy of minimally invasive intraoperative ultrasound in endoscopic pituitary surgery.

Pituitary
2025

A new method for repairing internal carotid artery rupture in skull base surgery: a case report and review of the literature.

Frontiers in surgery
2025

Rapid Endocrine Remission After ZAP-X Gyroscopic Radiosurgery for Cushing's Disease: A Case Report.

Cureus
2025

Clival Infiltrative Lesions: A Review of Differential Diagnosis Illustrated by a Rare Case of Coexisting Invasive Pituitary Adenoma and Clival Intravascular Lymphoma.

Journal of the Belgian Society of Radiology
2025

Structural and Functional Outcomes of Optic Pathway Compression in Pituitary Adenoma: A Prospective Pilot OCT Study.

Clinical ophthalmology (Auckland, N.Z.)
2025

A case report of atypical teratoid/rhabdoid tumor and pituitary adenoma collision tumor in the sellar region.

Frontiers in surgery
2025

Rebirth of an old modality: revisiting intraoperative ultrasound in pituitary surgery.

Pituitary
2025

From misclassified AIP variant to carney complex: a case report and retrospective evaluation of PRKAR1A in pituitary tumor predisposition.

Pituitary
2025

Validation and modification of the PANOMEN 3 classification for predicting long-term recurrence/progression and quality of life in patients with pituitary adenomas: a multicentre retrospective cohort study.

Pituitary
2025

Anemia in acromegaly: Prevalence, etiologies, and predictors from a large tertiary center cohort.

Pituitary
2026

Spontaneous regression of a growth hormone-secreting pituitary adenoma following thyroidectomy for toxic multinodular goiter with superior vena cava obstruction: Report of a rare case.

Medicine international
2025

Radiomics-based multiple machine learning approaches for investigating medial wall invasion of the cavernous sinus in pituitary adenomas.

Frontiers in oncology
2025

More Than a Headache: Unveiling Pituitary Apoplexy Following Acute Coronary Syndrome.

Cureus
2025

Ultrasound-Guided Jugular Vein Access for Inferior Petrosal Sinus Sampling: A Safe and Feasible Technique.

Cureus
2025

Osteoporosis and fragility fractures in patients with acromegaly: A two-center cross-sectional study.

World journal of orthopedics
2026

CAF-derived exosomes promote the proliferation and invasion of pituitary adenoma cells via miR-184 transfer.

Brain research bulletin
2025

Real-world burden of disease, treatment, and healthcare resource utilization in acromegaly: a quantitative survey of patient experiences.

Journal of patient-reported outcomes
2025

Dual Hormonal Presentation in a Rare Sellar Gangliocytoma: Diagnostic and Pathological Insights from a Collision Tumor.

Journal of neurological surgery reports
2025

Potentially radiation-induced late toxicity after irradiation of pituitary adenoma, a retrospective dosimetric study.

Radiation oncology (London, England)
2025

The Mystery of Elevated β-hCG in GnRH-Independent Precocious Puberty without a Detectable Tumor: A Six-Year Diagnostic Odyssey.

Hormone research in paediatrics
2025

Deciphering USP8's pivotal role in cancer: mechanisms, clinical insights and contrasts with its function in pituitary adenomas.

Journal of translational medicine
2025

Clinical, radiological, and pathological characteristics and long-term outcomes of silent corticotroph adenomas: a retrospective study.

BMC endocrine disorders
2025

Patient perceptions of pituitary incidentaloma diagnosis and follow-up: a Pituitary Society international patient survey.

Pituitary
2025

Pituitary tuberculosis in the pediatric population: a systematic review and case report.

Pituitary
2025

Trends of hospital-based reporting of intracranial neoplasms in Nigeria from 1960 to 2024: A systematic review and pooled analysis of literatures.

Neuro-oncology advances
2025

High-Risk Prostate Cancer in a Patient with Untreated Prolactinoma and Castrate-Level Testosterone Suppression: A Case Report.

Case reports in oncology
2025

Giant Prolactinoma Resistant to High-Dose Cabergoline in a Young Male Lost to Follow-Up.

Cureus
2026

Ki-67 and Preoperative Hypocortisolism are Predictive Factors for Postoperative Diabetes Insipidus After Endoscopic Pituitary Tumor Resection.

World neurosurgery
2026

Tumor characteristics and clinical outcomes in 113 patients with acromegaly: exploratory analysis of the role of histologic invasion of adjacent tissues.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2026

Very Long-Term Follow-Up of Multidimensional Health-Related Quality of Life After Endoscopic Endonasal Surgery for Pituitary Adenomas: A Prospective Cohort Study.

Head & neck
2025

Case Report: Management of a pregnancy complicated by a symptomatic macroprolactinoma.

Frontiers in medicine
2025

Therapeutic challenges of giant invasive cystic macroprolactinoma.

Endocrinology, diabetes & metabolism case reports
2025

Pituitary hormone deficiencies in prolactinomas: prevalence, predictors, and functional recovery.

Frontiers in endocrinology
2025

Acromegaly and breast cancer risk: evidence from a systematic review and meta-analysis.

Frontiers in endocrinology
2025

Transformation of Lactotroph Pituitary Adenoma to Metastatic Pituitary Carcinoma: A Case Report.

Cureus
2025

Unusual Presentation of Hypopituitarism Caused by Internal Carotid Artery Aneurysm.

Cureus
2025

A case of recurrent Cushing's disease with optimised perinatal outcomes.

Endocrinology, diabetes & metabolism case reports
2025

Development of a Novel Interpretable Transformer-Based Deep Learning Model for Predicting Postoperative Hypokalemia in Pituitary Adenomas.

Journal of evidence-based medicine
2026

Microarchitecture of the cavernous sinus walls: Clinical implications for pituitary adenomas.

Tissue & cell
2025

Immunohistochemical analysis of filamin a expression in acromegaly and its correlation with tumor characteristics and treatment response.

Scientific reports
2025

Pituitary Gland Metastases As the Initial Presentation of Lung Adenocarcinoma: A Case Report.

Cureus
2025

Severe Primary Hypothyroidism in a Child Presenting as a Pituitary Tumour: A Case Report.

Cureus
2025

Risk factors and predictive model for postoperative cerebrospinal fluid leakage following endoscopic endonasal pituitary adenoma surgery: a retrospective study focusing on pneumocephalus and sellar floor bony window.

Frontiers in endocrinology
2025

Evaluation of ChatGPT as a supplementary tool for pituitary adenomas: An observational study based on simulated consultations.

Medicine
2025

Loss of heterozygosity and absence of MAX immunostaining in a prolactinoma associated with multiple endocrine neoplasia type 5 (MEN5).

Pituitary
2025

Incidence and risk factors for transient and permanent central diabetes insipidus following pituitary adenoma surgery: a single center study.

The International journal of neuroscience
2025

Case Report: Bilateral lens dislocation as an atypical presentation of acromegaly and review of the ocular effects of GH/IGF-1 excess.

Frontiers in endocrinology
2025

[Consensus on the diagnosis and treatment of pituitary prolactinoma (2025 edition)].

Zhonghua yi xue za zhi
2025

[Refractory pituitary prolactinoma:current treatment status and challenges].

Zhonghua yi xue za zhi
2025

Proposed algorithm for early postoperative evaluation after endonasal endoscopic resection of pituitary adenomas with suprasellar extension.

Surgical neurology international
2025

Breast Cancer Metastasis to the Pituitary Presenting With Apoplexy.

Cureus
2025

Epidemiology, presentation and outcomes in pituitary apoplexy: a population-based study in Malta.

Endocrine oncology (Bristol, England)
2025

Radiolabeling molecular biomarkers of invasive pituitary adenomas: a narrative review.

Pituitary
2025

Incidence and characterization of spontaneous pituitary neuroendocrine tumors in aged spontaneously hypertensive rats.

Scientific reports
2026

Multiparameter MRI-based clinical-radiomic model to differentiate prolactinoma from hyperprolactinemic nonfunctioning pituitary adenoma.

Journal of neurosurgery
2025

Management of a mixed ACTH- and prolactin-secreting pituitary adenoma during pregnancy.

Endocrinology, diabetes & metabolism case reports
Ver todos os 3.759 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Adenoma hipofisário.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Adenoma hipofisário

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Long-term trajectories of cognitive function, fatigue, and quality of life in patients after pituitary adenoma surgery: A retrospective study.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia· 2026· PMID 41864128mais citado
  2. AI at the Sella Turcica: Multi-Model Large Language Model Evaluation in Pituitary Adenomas.
    Brain & spine· 2026· PMID 41859435mais citado
  3. Case Report: Treatment of hypersomatotropism in a diabetic dog with transsphenoidal hypophysectomy.
    Frontiers in veterinary science· 2026· PMID 41822230mais citado
  4. Regression of pituitary macroadenoma after endovascular embolization of thoracic cerebrospinal fluid-venous fistula for symptomatic intracranial hypotension: Illustrative case.
    Surgical neurology international· 2026· PMID 41783202mais citado
  5. Intraoperative Visual Evoked Potential Monitoring in Endoscopic Endonasal Surgery for Nonpituitary Adenoma Suprasellar Tumors.
    Journal of clinical neurology (Seoul, Korea)· 2026· PMID 41775377mais citado
  6. Systematic Review of the Molecular Basis for Cavernous Sinus Invasion in Somatotropinomas.
    Endocr Relat Cancer· 2026· PMID 41989873recente
  7. Amyloidogenic pituitary prolactinoma.
    Indian J Pathol Microbiol· 2026· PMID 41983748recente
  8. Selective resection of the medial wall of the cavernous sinus in acromegaly: patient series.
    J Neurosurg Case Lessons· 2026· PMID 41974060recente
  9. 3D volume growth rate may open new perspectives for the classification of aggressive pituitary adenomas.
    J Clin Endocrinol Metab· 2026· PMID 41973981recente
  10. Challenging the known: unusual case report of acromegaly and subclinical Cushing's disease combination.
    AME Case Rep· 2026· PMID 41971921recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:99408(Orphanet)
  2. MONDO:0006373(MONDO)
  3. GARD:19680(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q864296(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Adenoma hipofisário
Compêndio · Raras BR

Adenoma hipofisário

ORPHA:99408 · MONDO:0006373
CID-10
D35.2 · Neoplasia benigna da glândula hipófise (pituitária)
Ensaios
30 ativos
MedGen
UMLS
C0032000
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades